New hope for brain cancer: drug combo aims to extend survival
NCT ID NCT04922723
First seen May 05, 2026 · Last updated Jun 09, 2026 · Updated 5 times
Summary
This study tests whether adding the drug daratumumab to standard chemotherapy and radiation can help people with a newly diagnosed aggressive brain cancer called glioblastoma. About 16 participants will receive the combination treatment. The goal is to see if the new approach improves survival without causing severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West Virginia University Cancer Institute Mary Babb Randolph Cancer Center
Morgantown, West Virginia, 26506, United States
Conditions
Explore the condition pages connected to this study.